SHUBA SRINIVASAN: Open Payments
NPI 1497702328 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$820 in 35 payments from 19 companies in 2025. Trend: 2023 $176 · 2024 $522 · 2025 $820
Food & beverage: $820
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $100 |
| Myriad Genetic Laboratories, Inc. | 2 | $94 |
| ABBVIE INC. | 4 | $93 |
| Incyte Corporation | 4 | $83 |
| Janssen Biotech, Inc. | 4 | $67 |
| Celgene Corporation | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 2 | $45 |
| Gilead Sciences, Inc. | 1 | $34 |
| SERVIER PHARMACEUTICALS LLC | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
Products named: KEYTRUDA, MYRISK, EPKINLY, MONJUVI, REBLOZYL, JAKAFI, Trodelvy, Tibsovo.
Industry payments across TX — which companies pay providers there.
